Audentes Therapeutics, Inc. (BOLD) is now among the bigger bargains in its industry.
Within the last year the price ranged from $22 – 60 and there is a wide opportunity to get in. Its next earnings report will be released on Feb 26, 2020.

Intra-Cellular Therapies, Inc.(ITCI)

move, based on 2 analysts offering 12 month price targets for Intra-Cellular Therapies in the last 3 months. The average price target is $51.50 with a high forecast of $65.00 and a low forecast of $38.00. The average price target represents a 92.13% increase from the last price of $26.81.

Analysts like Sumant Kulkarni from Canaccord Genuity believe that we could see stock price minimum $65.00.

Another prominent analyst, Brian Abrahams of RBC Capital rates ITCI as a Buy. The rating was made just Last month.

Intra-Cellular Therapies, Inc.(ITCI) Recent News Reports

On average 6.3 articles are written each week about ITCI but this week 1 article were written and they were 68% Bullish and 32% Bearish.

Intra-Cellular Therapies, Inc. Target Levels

The market experts are predicting that ITCI is a Moderate Buy. Some other stocks to consider in this sector are:

PTGX
SYRS
RGNX